AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)	Clear-cell metastatic renal cell carcinoma, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder	Active, not recruiting	Phase 1 / Phase 2	2025-09-22		NCT06245915

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Arsenal Biosciences, Inc.	3

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
City of Hope	Duarte	United States	238
Dana Farber Cancer Institue	Boston	United States	1
Huntsman Cancer Institute - Univ of Utah Health	Salt Lake City	United States	1
Mayo Clinic Hospital	Phoenix	United States	41
MD Anderson Cancer Center	Houston	United States	589
Memorial Sloan Kettering Cancer Center	New York	United States	1000
Moffitt Cancer Center	Tampa	United States	523
Perlmutter Cancer Center - NYU Langone Health	New York	United States	3
University of Iowa and Holden Comprehensive Cancer Center	Iowa City	United States	2